Publikationen

Decoding Glioblastoma survival: Unraveling the prognostic potential of olfactory function in a prospective observational study. Oster et al. Neurological Research and Practice. 2025 (accepted)

Temporal Muscle Thickness as a Prognostic Marker in a Real-Life Cohort of Newly Diagnosed MGMT Promoter Methylated Glioblastoma: A Multicentric Imaging Analysis. Lazaridis L, Moenninghoff C, Bumes E, Spille DC, Müther M, Schulz T, Heider S, Agkatsev S, Schmidt T, Blau T, Oster C, Stummer W, Kessler AF, Seidel C, Grauer O, Hau P, Ahmadipour Y, Sure U, Keyvani K, Herrlinger U, Kleinschnitz C, Stuschke M, Guberina N, Herrmann K, Deuschl C, Scheffler B, Kebir S, Glas M. Cancer Med. 2025 Apr;14(8):e70689. doi: 10.1002/cam4.70689. PMID: 40260649

Cranioencephalic functional lymphoid units in glioblastoma. Dobersalske C, Rauschenbach L, Hua Y, Berliner C, Steinbach A, Grüneboom A, Kokkaliaris KD, Heiland DH, Berger P, Langer S, Tan CL, Stenzel M, Landolsi S, Weber F, Darkwah Oppong M, Werner RA, Gull H, Schröder T, Linsenmann T, Buck AK, Gunzer M, Stuschke M, Keyvani K, Forsting M, Glas M, Kipnis J, Steindler DA, Reinhardt HC, Green EW, Platten M, Tasdogan A, Herrmann K, Rambow F, Cima I, Sure U, Scheffler B. Nat Med. 2024 Oct; 30(10):2947-2956. doi: 10.1038/s41591-024-03152-x. Epub 2024 Jul 31. PMID: 39085419

Featured in Nature news & views: Skull bones harbour immune cells that are poised to target brain tumours Juyeun Lee, Justin D Lathia. Nature. 2024 Sep;633(8030):528-529. doi: 10.1038/d41586-024-02789-5. PMID: 39227751

KDM5B predicts temozolomide-resistant subclones in glioblastoma. Ullrich V, Ertmer S, Baginska A, Dorsch M, Gull HH, Cima I, Berger P, Dobersalske C, Langer S, Meyer L, Dujardin P, Kebir S, Glas M, Blau T, Keyvani K, Rauschenbach L, Sure U, Roesch A, Grüner BM, Scheffler B. iScience. 2023 Dec 3;27(1):108596. doi: 10.1016/j.isci.2023.108596. eCollection 2024 Jan 19. PMID: 38174322. Elected for special iScience issue "Phenotypic plasticity, cancer, and evolution", May 2024.

The Role of Fibroblast Activation Protein in Glioblastoma and Gliosarcoma: A Comparison of Tissue, 68Ga-FAPI-46 PET Data, and Survival Data. Oster C, Kessler L, Blau T, Keyvani K, Pabst KM, Fendler WP, Fragoso Costa P, Lazaridis L, Schmidt T, Feldheim J, Pierscianek D, Schildhaus HU, Sure U, Ahmadipour Y, Kleinschnitz C, Guberina N, Stuschke M, Deuschl C, Scheffler B, Herrmann K, Kebir S, Glas M. J Nucl Med. 2024 Aug 1;65(8):1217-1223. doi: 10.2967/jnumed.123.267151. PMID: 38960714.

Predictors and surgical outcome of hemorrhagic metastatic brain malignancies. Rauschenbach L, Kolbe P, Engel A, Ahmadipour Y, Oppong MD, Santos AN, Kebir S, Dobersalske C, Scheffler B, Deuschl C, Dammann P, Wrede KH, Sure U, Jabbarli R.J Neurooncol. 2024 May 27. doi: 10.1007/s11060-024-04714-2. Online ahead of print. PMID: 38801490.

Treatment Strategies for Glioblastoma in the Elderly: What Should We Focus on Compared to Younger Patients. Gull HH, Von Riegen AC, Beckmann GT, Ketelauri P, Walbrodt S, Santos AN, Oster C, Schmidt T, Glas M, Jabbarli R, Özkan N, Dammann P, Scheffler B, Sure U, Ahmadipour Y. Cancers (Basel). 2024 Mar 21;16(6):1231. doi: 10.3390/cancers16061231. PMID: 38539563.

The influence of radiological tumor growth pattern on sino‑nasal health in pituitary adenomas. Walbrodt S, Wrede KH, Chmielewski WX, Dinger TF, Schüβler M, Deuschl C, Chihi M, Gull HH, Jabbarli R, Oppong MD, Lenkeit A, Uerschels AK, Gembruch O, Kreitschmann-Andermahr I, Scheffler B, Sure U, Ahmadipour Y. Oncol Lett. 2024 Jan 26;27(3):125. doi: 10.3892/ol.2024.14258. eCollection 2024 Mar. PMID: 38333639.

A sequential targeting strategy interrupts AKT-driven subclone-mediated progression in glioblastoma. Kebir S, Ullrich V, Berger P, Dobersalske C, Langer S, Rauschenbach L, Trageser D, Till A, Lorbeer FK, Wieland A, Wilhelm-Buchstab T, Ahmad A, Fröhlich H, Cima I, Prasad S, Matschke J, Jendrossek V, Remke M, Grüner BM, Roesch A, Siveke JT, Herold-Mende C, Blau T, Keyvani K, van Landeghem FKH, Pietsch T, Felsberg J, Reifenberger G, Weller M, Sure U, Brüstle O, Simon M, Glas M, Scheffler B. Clin Cancer Res. 2023 Jan 17;29(2):488-500. doi: 10.1158/1078-0432.CCR-22-0611. PMID: 36239995.

Precision neuro-oncology: a pilot analysis of personalized treatment in recurrent glioma. Lazaridis L, Schmidt T, Oster C, Blau T, Pierscianek D, Siveke JT, Bauer S, Schildhaus HU, Sure U, Keyvani K, Kleinschnitz C, Stuschke M, Herrmann K, Deuschl C, Scheffler B*, Kebir S*, Glas M*. J Cancer Res Clin Oncol. 2022 Aug 12. doi: 10.1007/s00432-022-04050-w. Online ahead of print. PMID: 35953681, *shared.

Are we providing best-available care to newly diagnosed glioblastoma patients? Systematic review of phase III trials in newly diagnosed glioblastoma 2005-2022. Oster C, Schmidt T, Agkatsev S, Lazaridis L, Kleinschnitz C, Sure U, Scheffler B, Kebir S, Glas M. Neurooncol Adv. 2023 Sep 4;5(1):vdad105. doi: 10.1093/noajnl/vdad105. eCollection 2023 Jan-Dec. PMID: 37811538.

Heparins are potent inhibitors of ectonucleotide pyrophosphatase/phospho-diesterase-1 (NPP1) – a promising target for the immunotherapy of cancer. Lopez V, Schuh HJM, Mirza S, Vaaßen VJ, Schmidt MS, Sylvester K, Idris RM, Renn C, Schäkel L, Pelletier J, Sévigny J, Naggi A, Scheffler B, Lee SY, Bendas G, Müller CE. Front Immunol. 2023 Aug 29;14:1173634. doi: 10.3389/fimmu.2023.1173634. PMID: 37711611.

Telemedicine in Neuro-Oncology-An Evaluation of Remote Consultations during the COVID-19 Pandemic. Feldheim J, Schmidt T, Oster C, Feldheim J, Stuschke M, Stummer W, Grauer O, Scheffler B, Hagemann C, Sure U, Kleinschnitz C, Lazaridis L, Kebir S, Glas M. Cancers (Basel). 2023 Aug 11;15(16):4054. doi: 10.3390/cancers15164054. PMID: 37627083.

Feasibility and tolerability of trofosfamide and etoposide in progressive glioblastoma. Schmidt T, Agkatsev S, Feldheim J, Oster C, Blau T, Sure U, Keyvani K, Kleinschnitz C, Stuschke M, Herrmann K, Deuschl C, Scheffler B, Kebir S, Glas M, Lazaridis L. Neurooncol Adv. 2023 Jul 20;5(1):vdad090. doi: 10.1093/noajnl/vdad090. eCollection 2023 Jan-Dec. PMID: 37547266.

TERT expression is associated with metastasis from thin primaries, exhausted CD4+ T cells in melanoma and with DNA repair across cancer entities. Kuhn CK, Meister J, Kreft S, Stiller M, Puppel SH, Zaremba A, Scheffler B, Ullrich V, Schöneberg T, Schadendorf D, Horn S. PLoS One. 2023 Jul 7;18(7):e0281487. doi: 10.1371/journal.pone.0281487. eCollection 2023. PMID: 37418389.

Individual glioblastoma cells harbor both proliferative and invasive capabilities during tumor progression. Ratliff M, Karimian-Jazi K, Hoffmann DC, Rauschenbach L, Simon M, Hai L, Mandelbaum H, Schubert MC, Kessler T, Uhlig S, Azorin DD, Jung E, Osswald M, Solecki G, Maros ME, Venkataramani V, Glas M, Etminan N, Scheffler B, Wick W, Winkler F. Neuro Oncol. 2023 Jun 19:noad109. doi: 10.1093/neuonc/noad109. Online ahead of print. PMID: 37335907.

Surface Chemistry and Specific Surface Area rule the Efficiency of Gold Nanoparticle Sensitizers in Proton Therapy. Johny J, van Halteren CER, Cakir FC, Zwiehoff S, Behrends C, Bäumer C, Timmermann B, Rauschenbach L, Tippelt S, Scheffler B, Schramm A, Rehbock C, Barcikowski S. Chemistry. 2023 Jun 19:e202301260. doi: 10.1002/chem.202301260. Online ahead of print. PMID: 37334753.

Location of Recurrences after Trimodality Treatment for Glioblastoma with Respect to the Delivered Radiation Dose Distribution and Its Influence on Prognosis. Guberina N, Padeberg F, Pöttgen C, Guberina M, Lazaridis L, Jabbarli R, Deuschl C, Herrmann K, Blau T, Wrede KH, Keyvani K, Scheffler B, Hense J, Layer JP, Glas M, Sure U, Stuschke M. Cancers (Basel). 2023 May 30;15(11):2982. doi: 10.3390/cancers15112982. PMID: 37296942.

A novel serum extracellular vesicle protein signature to monitor glioblastoma tumor progression. Tzaridis T, Weller J, Bachurski D, Shakeri F, Schaub C, Hau P, Buness A, Schlegel U, Steinbach JP, Seidel C, Goldbrunner R, Schäfer N, Wechsler-Reya RJ, Hallek M, Scheffler B, Glas M, Haeberle L, Herrlinger U, Coch C, Reiners KS, Hartmann G. Int J Cancer. 2023 Jan 15;152(2):308-319. doi: 10.1002/ijc.34261. Epub 2022 Sep 17. PMID: 36054558.

First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma. Lazaridis L, Bumes E, Cäcilia Spille D, Schulz T, Heider S, Agkatsev S, Schmidt T, Blau T, Oster C, Feldheim J, Stummer W, Kessler AF, Seidel C, Grauer O, Hau P, Sure U, Keyvani K, Herrlinger U, Kleinschnitz C, Stuschke M, Herrmann K, Deuschl C, Breuer S, Hattingen E, Scheffler B, Kebir S, Glas M. Neurooncol Adv. 2022 Aug 24;4(1):vdac137. doi: 10.1093/noajnl/vdac137. eCollection 2022 Jan-Dec. PMID: 36284931.

The HHIP-AS1 lncRNA promotes tumorigenicity through stabilization of dynein complex 1 in human SHH-driven tumors. Bartl J, Zanini M, Bernardi F, Forget A, Blümel L, Talbot J, Picard D, Qin N, Cancila G, Gao Q, Nath S, Koumba IM, Wolter M, Kuonen F, Langini M, Beez T, Munoz C, Pauck D, Marquardt V, Yu H, Souphron J, Korsch M, Mölders C, Berger D, Göbbels S, Meyer FD, Scheffler B, Rotblat B, Diederichs S, Ramaswamy V, Suzuki H, Oro A, Stühler K, Stefanski A, Fischer U, Leprivier G, Willbold D, Steger G, Buell A, Kool M, Lichter P, Pfister SM, Northcott PA, Taylor MD, Borkhardt A, Reifenberger G, Ayrault O, Remke M. Nat Commun. 2022 Jul 13;13(1):4061. doi: 10.1038/s41467-022-31574-z. PMID: 35831316.

Machine Learning Applications for Differentiation of Glioma from Brain Metastasis-A Systematic Review. Jekel L, Brim WR, von Reppert M, Staib L, Cassinelli Petersen G, Merkaj S, Subramanian H, Zeevi T, Payabvash S, Bousabarah K, Lin M, Cui J, Brackett A, Mahajan A, Omuro A, Johnson MH, Chiang VL, Malhotra A, Scheffler B, Aboian MS. Cancers (Basel). 2022 Mar 8;14(6):1369. doi: 10.3390/cancers14061369. PMID: 35326526.

Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression. Cheung PF, Yang J, Fang R, Borgers A, Krengel K, Stoffel A, Althoff K, Yip CW, Siu EHL, Ng LWC, Lang KS, Cham LB, Engel DR, Soun C, Cima I, Scheffler B, Striefler JK, Sinn M, Bahra M, Pelzer U, Oettle H, Markus P, Smeets EMM, Aarntzen EHJG, Savvatakis K, Liffers ST, Lueong SS, Neander C, Bazarna A, Zhang X, Paschen A, Crawford HC, Chan AWH, Cheung ST, Siveke JT. Nat Commun. 2022 Jan 10;13(1):156. doi: 10.1038/s41467-021-27088-9. PMID: 35013174.

Tumor-associated hematopoietic stem and progenitor cells positively linked to glioblastoma progression. Lu IN, Dobersalske C, Rauschenbach L, Teuber-Hanselmann S, Steinbach A, Ullrich V, Prasad S, Blau T, Kebir S, Siveke JT, Becker JC, Sure U, Glas M, Scheffler B*, Cima I*. Nat Commun. 2021 Jun 23;12(1):3895. doi: 10.1038/s41467-021-23995-z.PMID: 34162860

Syllogist, a reference-based algorithm for cell type estimation (Version 0.1.0). Cima I, Dobersalske C, Scheffler B. Zenodo. http://doi.org/10.5281/zenodo.4782282. (2021, May 23).

Das Deutsche Konsortium für Translationale Krebsforschung. Dietrich A, Scheffler B, Eggert A, Peters C, Serve H, Schuler M, Schulze-Osthoff K, Weichert W, Wick W, Weyrich U, Baumann M, Krause M. FORUM 6-2021 „Krebsforschung in Deutschland". 2021. https://doi.org/10.1007/s12312-021-01014-y.

Analysis of Serum miRNA in Glioblastoma Patients: CD44-Based Enrichment of Extracellular Vesicles Enhances Specificity for the Prognostic Signature. Tzaridis T, Reiners KS, Weller J, Bachurski D, Schäfer N, Schaub C, Hallek M, Scheffler B, Glas M, Herrlinger U, Wild S, Coch C, Hartmann G. In: Extracellular Vesicles: Biology and Potentials in Cancer Therapeutics. pp347-362. Ed. William C.S.Cho. Int J Mol Sci. November 2021. MDPI. Reprinted from: Int J Mol Sci. 2020 Sep 29;21(19):7211. doi: 10.3390/ijms21197211.PMID: 33003586.

Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression. Cheung PF, Yang J, Fang R, Borgers A, Krengel K, Stoffel A, Althoff K, Yip CW, Siu EH, Ng LWC, Lang K, Cham L, Engel DR, Soun C, Cima I, Scheffler B, Striefler JK, Sinn M, Bahra M, Pelzer U, Oettle H, Markus P, Smeets EMM, Aarntzen EHJG, Savvatakis K, Liffers ST, Lueong S, Neander C, Bazarna A, Zhang X, Paschen A, Crawford H, Chan AWH, Cheung ST, and Siveke JT. Nat Commun. 2021 (in press) https://doi.org/10.1038/s41467-021-27088-9 .

How about Levetiracetam in Glioblastoma? An Institutional Experience and Meta-Analysis. Jabbarli R, Ahmadipour Y, Rauschenbach L, Santos AN, Darkwah Oppong M, Pierscianek D, Quesada CM, Kebir S, Dammann P, Guberina N, Scheffler B, Kaier K, Stuschke M, Sure U, Wrede KH. Cancers (Basel). 2021 Jul 27;13(15):3770. doi: 10.3390/cancers13153770.PMID: 34359673

Case Report: Pseudomeningeosis and Demyelinating Metastasis-Like Lesions From Checkpoint Inhibitor Therapy in Malignant Melanoma.Schmidt T, Kebir S, Livingstone E, Junker A, Zülow S, Lazaridis L, Oster C, Chorti E, Pierscianek D, Pul R, Keyvani K, Sure U, Stuschke M, Kleinschnitz C, Scheffler B, Zimmer L, Glas M. Front Oncol. 2021 Apr 15;11:637185. doi: 10.3389/fonc.2021.637185. eCollection 2021.PMID: 33937037

Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalities. Chorti E, Kebir S, Ahmed MS, Keyvani K, Umutlu L, Kanaki T, Zaremba A, Reinboldt-Jockenhoefer F, Knispel S, Gratsias E, Roesch A, Ugurel S, Scheffler B, Schadendorf D, Livingstone E, Meier F, Glas M, Zimmer L. Eur J Cancer. 2021 May;148:395-404. doi: 10.1016/j.ejca.2021.02.016. Epub 2021 Mar 28.PMID: 33789203

Machine learning-based differentiation between multiple sclerosis and glioma WHO II°-IV° using O-(2-[18F] fluoroethyl)-L-tyrosine positron emission tomography. Kebir S, Rauschenbach L, Weber M, Lazaridis L, Schmidt T, Keyvani K, Schäfer N, Milia A, Umutlu L, Pierscianek D, Stuschke M, Forsting M, Sure U, Kleinschnitz C, Antoch G, Colletti PM, Rubello D, Herrmann K, Herrlinger U, Scheffler B, Bundschuh RA, Glas M. J Neurooncol. 2021 Jan 27. doi: 10.1007/s11060-021-03701-1. Online ahead of print. PMID: 33502678.

Dosimetric impact of the positioning variation of tumor treating field electrodes in the PriCoTTF-phase I/II trial. Nour Y, Pöttgen C, Kebir S, Lazaridis L, Lüdemann L, Guberina M, Gauler T, Scheffler B, Jabbarli R, Pierscianek D, Sure U, Schmidt T, Oster C, Hau P, Glas M, Lübcke W, Stuschke M, Guberina N. J Appl Clin Med Phys. 2021 Jan 3. doi: 10.1002/acm2.13144. Online ahead of print.PMID: 33389825.

Preoperative and early postoperative seizures in patients with glioblastoma-two sides of the same coin? Ahmadipour Y, Rauschenbach L, Santos A, Darkwah Oppong M, Lazaridis L, Quesada CM, Junker A, Pierscianek D, Dammann P, Wrede KH, Scheffler B, Glas M, Stuschke M, Sure U, Jabbarli R. Neurooncol Adv. 2020 Nov 18;3(1):vdaa158. doi: 10.1093/noajnl/vdaa158. eCollection 2021 Jan-Dec. PMID: 33506201.

Establishment of a novel, cell-based autotaxin assay. Dobersalske C, Grundmann M, Timmermann A, Theisen L, Kölling F, Harris RC, Fuerstner C, Becker MS, Wunder F. Anal Biochem. 2021 Jul 31;630:114322. doi: 10.1016/j.ab.2021.114322. Online ahead of print.PMID: 34343482

Genetic knockdown of Klk8 has sex-specific multi-targeted therapeutic effects on Alzheimer's pathology in mice. Herring A, Kurapati NK, Krebs S, Grammon N, Scholz LM, Voss G, Miah MR, Budny V, Mairinger F, Haase K, Teuber-Hanselmann S, Dobersalske C, Schramm S, Jöckel KH, Münster Y, Keyvani K.Neuropathol Appl Neurobiol. 2021 Aug;47(5):611-624. doi: 10.1111/nan.12687. Epub 2021 Jan 27.PMID: 33341972

Radiotherapy is associated with a deletion signature that contributes to poor outcomes in patients with cancer. Kocakavuk E, Anderson KJ, Varn FS, Johnson KC, Amin SB, Sulman EP, Lolkema MP, Barthel FP, Verhaak RGW. Nat Genet. 2021 Jul;53(7):1088-1096. doi: 10.1038/s41588-021-00874-3. Epub 2021 May 27.PMID: 34045764

Drug repositioning of antiretroviral ritonavir for combinatorial therapy in glioblastoma. Rauschenbach L, Wieland A, Reinartz R, Kebir S, Till A, Darkwah Oppong M, Dobersalske C, Ullrich V, Ahmad A, Jabbarli R, Pierscianek D, Fröhlich H, Simon M, Brüstle O, Sure U, Glas M, Scheffler B. Eur J Cancer. 2020 Nov;140:130-139. doi: 10.1016/j.ejca.2020.09.017. Epub 2020 Oct 19.PMID: 33091717.

Olfactory function as an independent prognostic factor in glioblastoma. Kebir S, Hattingen E, Niessen M, Rauschenbach L, Fimmers R, Hummel T, Schäfer N, Lazaridis L, Kleinschnitz C, Herrlinger U, Scheffler B*, Glas M*. Neurology. 2020 Feb 4;94(5):e529-e537. doi: 10.1212/WNL.0000000000008744. Epub 2019 Dec 12. PMID: 31831598 (*shared authors).

Analysis of Serum miRNA in Glioblastoma Patients: CD44-Based Enrichment of Extracellular Vesicles Enhances Specificity for the Prognostic Signature. Tzaridis T, Reiners KS, Weller J, Bachurski D, Schäfer N, Schaub C, Hallek M, Scheffler B, Glas M, Herrlinger U, Wild S, Coch C, Hartmann G. Int J Mol Sci. 2020 Sep 29;21(19):7211. doi: 10.3390/ijms21197211.PMID: 33003586.

Challenging Implications of Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids Syndrome with an Atypical Presentation: Report of Two Cases. Rauschenbach L, Kebir S, Radbruch A, Darkwah Oppong M, Gembruch O, Teuber-Hanselmann S, Gielen GH, Scheffler B, Glas M, Sure U, Lemonas E. World Neurosurg. 2020 Nov;143:507-512.e1. doi: 10.1016/j.wneu.2020.07.123. Epub 2020 Jul 22. PMID: 32711135.

Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma. Zhang X, Zegar T, Weiser T, Hamdan FH, Berger BT, Lucas R, Balourdas DI, Ladigan S, Cheung PF, Liffers ST, Trajkovic-Arsic M, Scheffler B, Joerger AC, Hahn SA, Johnsen SA, Knapp S, Siveke JT. Int J Cancer. 2020 Nov 15;147(10):2847-2861. doi: 10.1002/ijc.33137. Epub 2020 Jun 29. PMID: 32599645.

Dosimetric impact of the positioning variation of tumor treating field electrodes in the PriCoTTF-phase I/II trial. Nour Y, Pöttgen C, Kebir S, Lazaridis L, Lüdemann L, Guberina M, Gauler T, Scheffler B, Jabbarli R, Pierscianek D, Sure U, Schmidt T, Oster C, Hau P, Glas M, Lübcke W, Stuschke M, Guberina N. J Appl Clin Med Phys. 2021 Jan;22(1):242-250. doi: 10.1002/acm2.13144. Epub 2021 Jan 3. PMID: 33389825.

Plasma Next Generation Sequencing and Droplet Digital-qPCR-Based Quantification of Circulating Cell-Free RNA for Noninvasive Early Detection of Cancer. Metzenmacher M, Váraljai R, Hegedüs B, Cima I, Forster J, Schramm A, Scheffler B, Horn PA, Klein CA, Szarvas T, Reis H, Bielefeld N, Roesch A, Aigner C, Kunzmann V, Wiesweg M, Siveke JT, Schuler M, Lueong SS. Cancers (Basel). 2020 Feb 4;12(2):353. doi: 10.3390/cancers12020353. PMID: 32033141.

Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma. Lazaridis L, Schäfer N, Teuber-Hanselmann S, Blau T, Schmidt T, Oster C, Weller J, Tzaridis T, Pierscianek D, Keyvani K, Kleinschnitz C, Stuschke M, Scheffler B, Deuschl C, Sure U, Herrlinger U, Kebir S, Glas M. J Cancer Res Clin Oncol. 2020 Mar;146(3):787-792. doi: 10.1007/s00432-019-03106-8. Epub 2019 Dec 11. PMID: 31828428.

Exosome/microvesicle content is altered in leucine-rich repeat kinase 2 mutant induced pluripotent stem cell-derived neural cells. Candelario KM, Balaj L, Zheng T, Skog J, Scheffler B, Breakefield X, Schüle B, Steindler DA. J Comp Neurol. 2020 May;528(7):1203-1215. doi: 10.1002/cne.24819. Epub 2019 Nov 30. PMID: 31743443.

Genetic knockdown of Klk8 has sex-specific multi-targeted therapeutic effects on Alzheimer's pathology in mice. Herring A, Kurapati NK, Krebs S, Grammon N, Scholz LM, Voss G, Miah MR, Budny V, Mairinger F, Haase K, Teuber-Hanselmann S, Dobersalske C, Schramm S, Jöckel KH, Münster Y, Keyvani K. Neuropathol Appl Neurobiol. 2020 Dec 20. doi: 10.1111/nan.12687. Online ahead of print.PMID: 33341972.

The genetic landscape of choroid plexus tumors in children and adults.Thomas C, Soschinski P, Zwaig M, Oikonomopoulos S, Okonechnikov K, Pajtler KW, Sill M, Schweizer L, Koch A, Neumann J, Schüller U, Sahm F, Rauschenbach L, Keyvani K, Proescholdt M, Riemenschneider MJ, Segewiß J, Ruckert C, Grauer O, Monoranu CM, Lamszus K, Patrizi A, Kordes U, Siebert R, Kool M, Ragoussis J, Foulkes WD, Paulus W, Rivera B, Hasselblatt M. Neuro Oncol. 2020 Nov 29:noaa267. doi: 10.1093/neuonc/noaa267. Online ahead of print.PMID: 33249490.

A Preliminary Study on Machine Learning-Based Evaluation of Static and Dynamic FET-PET for the Detection of Pseudoprogression in Patients with IDH-Wildtype Glioblastoma. Kebir S, Schmidt T, Weber M, Lazaridis L, Galldiks N, Langen KJ, Kleinschnitz C, Hattingen E, Herrlinger U, Lohmann P, Glas M. Cancers (Basel). 2020 Oct 22;12(11):3080. doi: 10.3390/cancers12113080. PMID: 33105661.

Single Cell Hydrodynamic Stretching and Microsieve Filtration Reveal Genetic, Phenotypic and Treatment-Related Links to Cellular Deformability. Li F, Cima I, Vo JH, Tan MH, Ohl CD. Micromachines (Basel). 2020 May 9;11(5):486. doi: 10.3390/mi11050486.PMID: 32397447.

Applying next-generation sequencing to unravel the mutational landscape in viral quasispecies. Lu IN, Muller CP, He FQ. Virus Res. 2020 Jul 2;283:197963. doi: 10.1016/j.virusres.2020.197963. Epub 2020 Apr 9.PMID: 32278821.

Comparative Molecular Life History of Spontaneous Canine and Human Gliomas. Amin SB, Anderson KJ, Boudreau CE, Martinez-Ledesma E, Kocakavuk E, Johnson KC, Barthel FP, Varn FS, Kassab C, Ling X, Kim H, Barter M, Lau CC, Ngan CY, Chapman M, Koehler JW, Long JP, Miller AD, Miller CR, Porter BF, Rissi DR, Mazcko C, LeBlanc AK, Dickinson PJ, Packer RA, Taylor AR, Rossmeisl JH Jr, Woolard KD, Heimberger AB, Levine JM, Verhaak RGW. Cancer Cell. 2020 Feb 10;37(2):243-257.e7. doi: 10.1016/j.ccell.2020.01.004.PMID: 32049048.

Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors. Schäfer N, Gielen GH, Rauschenbach L, Kebir S, Till A, Reinartz R, Simon M, Niehusmann P, Kleinschnitz C, Herrlinger U, Pietsch T, Scheffler B*, Glas M*. J Transl Med. 2019 Mar 20;17(1):96. doi: 10.1186/s12967-019-1846-y. PMID: 30894200 (*shared last authors).

Simultaneous primary cancer occurrence of melanoma and pulmonary adenocarcinoma in leptomeningeal metastases: a case report. Stoppek AK, Kebir S, Junker A, Keyvani K, Zülow S, Lazaridis L, Schmidt T, Pierscianek D, Stuschke M, Sure U, Kleinschnitz C, Scheffler B, Zimmer L, Glas M. BMC Cancer. 2019 Oct 23;19(1):995. doi: 10.1186/s12885-019-6183-2. PMID: 31646997.

3D extracellular matrix microenvironment in bioengineered tissue models of primary pediatric and adult brain tumors. Sood D, Tang-Schomer M, Pouli D, Mizzoni C, Raia N, Tai A, Arkun K, Wu J, Black LD 3rd, Scheffler B, Georgakoudi I, Steindler DA, Kaplan DL. Nat Commun. 2019 Oct 4;10(1):4529. doi: 10.1038/s41467-019-12420-1. PMID: 31586101.

Comparison of L-Methyl-11C-Methionine PET With Magnetic Resonance Spectroscopy in Detecting Newly Diagnosed Glioma. Kebir S, Lazaridis L, Weber M, Deuschl C, Stoppek AK, Schmidt T, Mönninghoff C, Blau T, Keyvani K, Umutlu L, Pierscianek D, Forsting M, Stuschke M, Antoch G, Sure U, Kleinschnitz C, Scheffler B, Colletti PM, Rubello D, Herrmann K, Glas M. Clin Nucl Med. 2019 Jun;44(6):e375-e381. doi: 10.1097/RLU.0000000000002577. PMID: 30985412.

Regorafenib in patients with recurrent high-grade astrocytoma. Kebir S, Rauschenbach L, Radbruch A, Lazaridis L, Schmidt T, Stoppek AK, Pierscianek D, Stuschke M, Forsting M, Sure U, Keyvani K, Kleinschnitz C, Scheffler B, Glas M. J Cancer Res Clin Oncol. 2019 Apr;145(4):1037-1042. doi: 10.1007/s00432-019-02868-5. Epub 2019 Feb 28. PMID: 30820715.

Sequence-dependent cross-resistance of combined radiotherapy plus BRAF^V600E inhibition in melanoma. Shannan B, Matschke J, Chauvistré H, Vogel F, Klein D, Meier F, Westphal D, Bruns J, Rauschenberg R, Utikal J, Forschner A, Berking C, Terheyden P, Dabrowski E, Gutzmer R, Rafei-Shamsabadi D, Meiss F, Heinzerling L, Zimmer L, Livingstone E, Váraljai R, Hoewner A, Horn S, Klode J, Stuschke M, Scheffler B, Marchetto A, Sannino G, Grünewald TGP, Schadendorf D, Jendrossek V, Roesch A. Eur J Cancer. 2019 Mar;109:137-153. doi: 10.1016/j.ejca.2018.12.024.Epub 2019 Feb 2.PMID: 30721788.

Xenografting for disease modeling of intramedullary spinal cord tumors: a systematic review. Rauschenbach L, Kocakavuk E, Pierscianek D, Ahmadipour Y, Kebir S, Glas M, Scheffler B, Sure U, Jabbarli R. Spinal Cord. 2019 Jun;57(6):439-448. doi: 10.1038/s41393-019-0248-6. Epub 2019 Feb 1. PMID: 30710121.

Hybrid 11C-MET PET/MRI Combined With „Machine Learning" in Glioma Diagnosis According to the Revised Glioma WHO Classification 2016. Kebir S, Weber M, Lazaridis L, Deuschl C, Schmidt T, Mönninghoff C, Keyvani K, Umutlu L, Pierscianek D, Forsting M, Sure U, Stuschke M, Kleinschnitz C, Scheffler B, Colletti PM, Rubello D, Rischpler C, Glas M. Clin Nucl Med. 2019 Mar;44(3):214-220. doi: 10.1097/RLU.0000000000002398. PMID: 30516675.

Longitudinal molecular trajectories of diffuse glioma in adults. Barthel FP, Johnson KC, Varn FS, Moskalik AD, Tanner G, Kocakavuk E, Anderson KJ, Abiola O, Aldape K, Alfaro KD, Alpar D, Amin SB, Ashley DM, Bandopadhayay P, Barnholtz-Sloan JS, Beroukhim R, Bock C, Brastianos PK, Brat DJ, Brodbelt AR, Bruns AF, Bulsara KR, Chakrabarty A, Chakravarti A, Chuang JH, Claus EB, Cochran EJ, Connelly J, Costello JF, Finocchiaro G, Fletcher MN, French PJ, Gan HK, Gilbert MR, Gould PV, Grimmer MR, Iavarone A, Ismail A, Jenkinson MD, Khasraw M, Kim H, Kouwenhoven MCM, LaViolette PS, Li M, Lichter P, Ligon KL, Lowman AK, Malta TM, Mazor T, McDonald KL, Molinaro AM, Nam DH, Nayyar N, Ng HK, Ngan CY, Niclou SP, Niers JM, Noushmehr H, Noorbakhsh J, Ormond DR, Park CK, Poisson LM, Rabadan R, Radlwimmer B, Rao G, Reifenberger G, Sa JK, Schuster M, Shaw BL, Short SC, Smitt PAS, Sloan AE, Smits M, Suzuki H, Tabatabai G, Van Meir EG, Watts C, Weller M, Wesseling P, Westerman BA, Widhalm G, Woehrer A, Yung WKA, Zadeh G, Huse JT, De Groot JF, Stead LF, Verhaak RGW; GLASS Consortium. Nature. 2019 Dec;576(7785):112-120. doi: 10.1038/s41586-019-1775-1. Epub 2019 Nov 20.PMID: 31748746.

Recent advances in microfluidic methods in cancer liquid biopsy.Iliescu FS, Poenar DP, Yu F, Ni M, Chan KH, Cima I, Taylor HK, Cima I, Iliescu C. Biomicrofluidics. 2019 Jul 23;13(4):041503. doi: 10.1063/1.5087690. eCollection 2019 Jul.PMID: 31431816.

Blood-Based Biomarkers in High Grade Gliomas: a Systematic Review. Pierscianek D, Ahmadipour Y, Oppong MD, Rauschenbach L, Kebir S, Glas M, Sure U, Jabbarli R. Mol Neurobiol. 2019 Sep;56(9):6071-6079. doi: 10.1007/s12035-019-1509-2. Epub 2019 Feb 4.PMID: 30719642.

Health-related quality of life and neurocognitive functioning with lomustine-temozolomide vs temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial. Weller J, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Hau P, Krex D, Grauer O, Goldbrunner R, Bähr O, Uhl M, Seidel C, Tabatabai G, Brehmer S, Bullinger L, Galldiks N, Schaub C, Kebir S, Stummer W, Simon M, Fimmers R, Coch C, Glas M, Herrlinger U, Schäfer N. Lancet Oncol. 2019 Oct;20(10):1444-1453. doi: 10.1016/S1470-2045(19)30502-9. Epub 2019 Sep 2.PMID: 31488360.

Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF. Di Tacchio M, Macas J, Weissenberger J, Sommer K, Bähr O, Steinbach JP, Senft C, Seifert V, Glas M, Herrlinger U, Krex D, Meinhardt M, Weyerbrock A, Timmer M, Goldbrunner R, Deckert M, Scheel AH, Büttner R, Grauer OM, Schittenhelm J, Tabatabai G, Harter PN, Günther S, Devraj K, Plate KH, Reiss Y. Cancer Immunol Res. 2019 Dec;7(12):1910-1927. doi: 10.1158/2326-6066.CIR-18-0865. Epub 2019 Oct 9.PMID: 31597643.

Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial. Kebir S, Schaub C, Junold N, Hattingen E, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Galldiks N, Weller J, Mack F, Tzaridis T, Bähr O, Seidel C, Schlegel U, Schmidt-Graf F, Rohde V, Borchers C, Tabatabai G, Hänel M, Sabel M, Gerlach R, Krex D, Belka C, Vatter H, Proescholdt M, Glas M, Herrlinger U. J Neurooncol. 2019 Sep;144(3):501-509. doi: 10.1007/s11060-019-03246-4. Epub 2019 Jul 19.PMID: 31325144.

Association of Surgical Resection, Disability, and Survival in Patients with Glioblastoma. Ahmadipour Y, Kaur M, Pierscianek D, Gembruch O, Oppong MD, Mueller O, Jabbarli R, Glas M, Sure U, El Hindy N. J Neurol Surg A Cent Eur Neurosurg. 2019 Jul;80(4):262-268. doi: 10.1055/s-0039-1685170. Epub 2019 Apr 9.PMID: 30965373.

Blood-Based Biomarkers in High Grade Gliomas: a Systematic Review. Pierscianek D, Ahmadipour Y, Oppong MD, Rauschenbach L, Kebir S, Glas M, Sure U, Jabbarli R. Mol Neurobiol. 2019 Sep;56(9):6071-6079. doi: 10.1007/s12035-019-1509-2. Epub 2019 Feb 4.PMID: 30719642.

Lomustine-temozolomide combination therapy versus standardtemozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schäfer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M; Neurooncology Working Group of the German Cancer Society. Lancet. 2019 Feb 16;393(10172):678-688. doi: 10.1016/S0140-6736(18)31791-4. Epub 2019 Feb 14.PMID: 30782343.

Targeting the Post-Irradiation Tumor Microenvironment in Glioblastoma via Inhibition of CXCL12. Giordano FA, Link B, Glas M, Herrlinger U, Wenz F, Umansky V, Brown JM, Herskind C. Cancers (Basel). 2019 Feb 26;11(3):272. doi: 10.3390/cancers11030272.PMID: 30813533.

Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma (INTRAGO): An Open-Label, Dose-Escalation Phase I/II Trial. Giordano FA, Brehmer S, Mürle B, Welzel G, Sperk E, Keller A, Abo-Madyan Y, Scherzinger E, Clausen S, Schneider F, Herskind C, Glas M, Seiz-Rosenhagen M, Groden C, Hänggi D, Schmiedek P, Emami B, Souhami L, Petrecca K, Wenz F. Neurosurgery. 2019 Jan 1;84(1):41-49. doi: 10.1093/neuros/nyy018.PMID: 29528443.

Association of Surgical Resection, Disability, and Survival in Patients with Glioblastoma. Ahmadipour Y, Kaur M, Pierscianek D, Gembruch O, Oppong MD, Mueller O, Jabbarli R, Glas M, Sure U, El Hindy N. J Neurol Surg A Cent Eur Neurosurg. 2019 Jul;80(4):262-268. doi: 10.1055/s-0039-1685170. Epub 2019 Apr 9.PMID: 30965373.

Recurrent pseudoprogression in isocitrate dehydrogenase 1 mutant glioblastoma. Kebir S, Rauschenbach L, Gielen GH, Schäfer N, Tzaridis T, Scheffler B, Giordano FA, Lazaridis L, Herrlinger U, Glas M. J Clin Neurosci. 2018 Jul;53:255-258. doi: 10.1016/j.jocn.2018.04.056. Epub 2018 May 10. PMID: 29754968.

Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial. Schaub C, Kebir S, Junold N, Hattingen E, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Niessen M, Mack F, Stuplich M, Tzaridis T, Bähr O, Kortmann RD, Schlegel U, Schmidt-Graf F, Rohde V, Braun C, Hänel M, Sabel M, Gerlach R, Krex D, Belka C, Vatter H, Proescholdt M, Herrlinger U, Glas M. J Cancer Res Clin Oncol. 2018 Aug;144(8):1581-1589. doi: 10.1007/s00432-018-2671-z. Epub 2018 May 28.PMID: 29808316.

Quality of life in the GLARIUS trial randomizing bevazizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. Schäfer N, Proescholdt M, Steinbach JP, Weyerbrock A, Hau P, Grauer O, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Grau S, Hänel M, Schnell O, Krex D, Vajkoczy P, Tabatabai G, Mack F, Schaub C, Tzaridis T, Nießen M, Kebir S, Leutgeb B, Urbach H, Belka C, Stummer W, Glas M, Herrlinger U. Neuro Oncol. 2018 Jun 18;20(7):975-985. doi: 10.1093/neuonc/nox204.PMID: 29121274.

11C-MET PET/MRI for detection of recurrent glioma. Deuschl C, Kirchner J, Poeppel TD, Schaarschmidt B, Kebir S, El Hindy N, Hense J, Quick HH, Glas M, Herrmann K, Umutlu L, Moenninghoff C, Radbruch A, Forsting M, Schlamann M. Eur J Nucl Med Mol Imaging. 2018 Apr;45(4):593-601. doi: 10.1007/s00259-017-3916-9. Epub 2017 Dec 28.PMID: 29282517.

Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields: initial experience. Ceccon G, Lazaridis L, Stoffels G, Rapp M, Weber M, Blau T, Lohmann P, Kebir S, Herrmann K, Fink GR, Langen KJ, Glas M, Galldiks N. Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1626-1635. doi: 10.1007/s00259-018-3992-5. Epub 2018 Mar 21.PMID: 29564490.

Functional Subclone Profiling for Prediction of Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human Glioblastoma. Reinartz R, Wang S, Kebir S, Silver DJ, Wieland A, Zheng T, Küpper M, Rauschenbach L, Fimmers R, Shepherd TM, Trageser D, Till A, Schäfer N, Glas M, Hillmer AM, Cichon S, Smith AA, Pietsch T, Liu Y, Reynolds BA, Yachnis A, Pincus DW, Simon M, Brüstle O, Steindler DA, Scheffler B. Clin Cancer Res. 2017 Jan 15;23(2):562-574. doi: 10.1158/1078-0432.CCR-15-2089. Epub 2016 Aug 12. PMID: 27521447.

Unsupervised consensus cluster analysis of [18F]-fluoroethyl-L-tyrosine positron emission tomography identified textural features for the diagnosis of pseudoprogression in high-grade glioma. Kebir S, Khurshid Z, Gaertner FC, Essler M, Hattingen E, Fimmers R, Scheffler B, Herrlinger U, Bundschuh RA, Glas M. Oncotarget. 2017 Jan 31;8(5):8294-8304. doi: 10.18632/oncotarget.14166. PMID: 28030820.

Quantitative T1-mapping detects cloudy-enhancing tumor compartments predicting outcome of patients with glioblastoma. Müller A, Jurcoane A, Kebir S, Ditter P, Schrader F, Herrlinger U, Tzaridis T, Mädler B, Schild HH, Glas M, Hattingen E. Cancer Med. 2017 Jan;6(1):89-99. doi: 10.1002/cam4.966. Epub 2016 Nov 28. PMID: 27891815.

Early whole brain radiotherapy in primary CNS lymphoma: negative impact on quality of life in the randomized G-PCNSL-SG1 trial. Herrlinger U, Schäfer N, Fimmers R, Griesinger F, Rauch M, Kirchen H, Roth P, Glas M, Bamberg M, Martus P, Thiel E, Korfel A, Weller M.J Cancer Res Clin Oncol. 2017 Sep;143(9):1815-1821. doi: 10.1007/s00432-017-2423-5. Epub 2017 Apr 22.PMID: 28434043.

Value of quantitative magnetic resonance imaging T1-relaxometry in predicting contrast-enhancement in glioblastoma patients. Hattingen E, Müller A, Jurcoane A, Mädler B, Ditter P, Schild H, Herrlinger U, Glas M, Kebir S. Oncotarget. 2017 Jun 27;8(32):53542-53551. doi: 10.18632/oncotarget.18612. eCollection 2017 Aug 8.PMID: 28881830.

Phase I trial of dovitinib (TKI258) in recurrent glioblastoma. Schäfer N, Gielen GH, Kebir S, Wieland A, Till A, Mack F, Schaub C, Tzaridis T, Reinartz R, Niessen M, Fimmers R, Simon M, Coch C, Fuhrmann C, Herrlinger U, Scheffler B*, Glas M*. J Cancer Res Clin Oncol. 2016 Jul;142(7):1581-9. doi: 10.1007/s00432-016-2161-0. Epub 2016 Apr 21. PMID: 27100354 *co-senior authors.

Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases. Kebir S, Rauschenbach L, Galldiks N, Schlaak M, Hattingen E, Landsberg J, Bundschuh RA, Langen KJ, Scheffler B, Herrlinger U, Glas M. Neuro Oncol. 2016 Oct;18(10):1462-4. doi: 10.1093/neuonc/now154. Epub 2016 Sep 2. PMID: 27591333.

Therapy of leptomeningeal metastasis in solid tumors. Mack F, Baumert BG, Schäfer N, Hattingen E, Scheffler B, Herrlinger U, Glas M. Cancer Treat Rev. 2016 Feb;43:83-91. doi: 10.1016/j.ctrv.2015.12.004. Epub 2015 Dec 24. PMID: 26827696.

Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET. Kebir S, Fimmers R, Galldiks N, Schäfer N, Mack F, Schaub C, Stuplich M, Niessen M, Tzaridis T, Simon M, Stoffels G, Langen KJ, Scheffler B, Glas M, Herrlinger U. Clin Cancer Res. 2016 May 1;22(9):2190-6. doi: 10.1158/1078-0432.CCR-15-1334. Epub 2015 Dec 16. PMID: 26673798.

Evolutionary trends and functional anatomy of the human expanded autophagy network. Till A, Saito R, Merkurjev D, Liu JJ, Syed GH, Kolnik M, Siddiqui A, Glas M, Scheffler B, Ideker T, Subramani S. Autophagy. 2015;11(9):1652-67. doi: 10.1080/15548627.2015.1059558. PMID: 26103419.